

REMARKS

Applicants respectfully submit that the Sequence Listing are submitted solely in response to the Office's requirement in compliance with 37 C.F.R. 1.821-1.825. The amendments in the specification merely conform reference to Sequence Nos. in the specification to the content of the Sequence Listing.

Applicants have recently recognized inaccuracies in the originally submitted sequence information. In light of this, a replacement Sequence Listing is submitted herewith, presenting the sequence information without the inaccuracies. The replacement sequence information provided herewith does not introduce new matter as all sequence information is supported by the attached Declaration of the inventors verifying that they have been in continuous possession of the original clone of an exemplary invention receptor, and that the revised sequence information provided herewith is derived from the same clone from which the original sequence information was obtained. The replacement sequence listing corrects inaccuracies in the originally submitted sequence listing at four locations in SEQ ID NO:1 and three locations in SEQ ID NO:2, as follows: (i) at nucleotide position 583-585, resulting in start codon for amino acid methionine (in place of leucine) at residue 1; (ii) at nucleotide position 1141, T instead of C, resulting in the codon for amino acid serine (in place of proline) at residue 187; (iii) at nucleotide positions 1224 and 1280, nucleotide corrections resulting in a reading frame shift in amino acids 215 to 233; (iv) at nucleotide 1872, T instead of C, resulting in no change in the encoded amino acid; and (v) in the 3'-untranslated region, eleven single nucleotide corrections.

In re application of
Evans et al.
Appl. No. 10/081,555
Page 4

Atty. Dkt. No. SALK 2270-5
(088802-5212)

In view of the above amendments and remarks, prompt and favorable action on this application is respectfully requested. In the event issues remain to be resolved, the Examiner is invited to contact the undersigned by telephone so that a prompt disposition of this application can be achieved.

Date 11/19/02

FOLEY & LARDNER
P.O. Box 80278
San Diego, California 92138-0278
Telephone: (858) 847-6711
Facsimile: (858) 792-6773

Respectfully submitted,

By Lei Fang

Lei Fang, Reg. No. 44,676
For Stephen E. Reiter
Attorney for Applicant
Registration No. 31,192

APPENDIX A: A MARK-UP VERSION OF THE REPLACEMENT PARAGRAPHS, INDICATING THE CHANGES

[0061] Examples of response elements suitable for use in practice of the invention methods can be selected from the following:

DR-3,4,5 = AGGTCANnAGGTCA, wherein n is 3, 4, or 5 (SEQ ID NOs: [15, 16 and 17] 44, 45 and 46);

β DR-3,4,5 = AGTTCANnTGAACT, wherein n is 3, 4 or 5 (SEQ ID NOs: 47, 48 and 22); and

IR-6 = TGA'ACTNnAGGTCA, wherein n is 6 (SEQ ID NO: 23), and the like.

[0062] Those of skill in the art will recognize that any combination of nucleotides can be used to make up the 3, 4, 5, or 6 nucleotide space between the repeated half sites (*i.e.*, Nn in SEQ ID NOs: [15, 16, 17] 44, 45, 46, 22 or 23).